Unknown Manufacturer
Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Efalizumab is a monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Efalizumab binds to CD11a, a subunit of leukocyte function antigen-1 (LFA-1), which is expressed on all leukocytes. As a result efalizumab decreases cell surface expression of CD11a.
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
1 associated conditions
